CEP-32496 is a kinase inhibitor that has multikinase binding activity but remains selectively cytotoxic for mutant (V600E) B-Raf (versus WT); it exhibits anticancer chemotherapeutic activity. Also contributing to the ability of CEP-32496 to inhibit cell proliferation, this compound inhibits pMEK and mERK in animal models with tumors containing the mutant B-Raf.
| Cas No. | 1188910-76-0 |
|---|---|
| Purity | ≥98% |
| Formula | C24H22F3N5O5 |
| Formula Wt. | 517.46 |
| Chemical Name | Urea, N-[3-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N-[5-(2,2,2-trifluoro-1,1-dimethylethyl)-3-isoxazolyl]- |
| IUPAC Name | 1-[3-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-3-[4-(1,1, 1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]urea |
| Solubility | DMSO 9 mg/mL (17.39 mM) Water Insoluble Ethanol Insoluble |
| Appearance | White to off white powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet | |
| Brochures |
James J, Ruggeri B, Armstrong RC, et al. CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity. Mol Cancer Ther. 2012 Apr;11(4):930-41. PMID: 22319199.
Rowbottom MW, Faraoni R, Chao Q, et al. Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E. J Med Chem. 2012 Feb 9;55(3):1082-105. PMID: 22168626.
